Gout: Symptoms, Treatment & When to Seek Care

Gout is a crystal deposition disease in which supersaturation of urate leads to formation of monosodium urate monohydrate crystals in synovial fluid, cartilage surfaces, tendons, and—when disease advances—subcutaneous tissues as tophi. The innate immune system recognises those crystals, activating the NLRP3 inflammasome and releasing interleukin-1β and other mediators that produce the sudden, intensely painful monoarthritis that clinicians associate with a typical flare.

Hyperuricemia precedes clinically apparent gout in most patients, yet not every person with an elevated serum urate will ever flare. Once flares begin, the natural history often progresses through repeated attacks separated by variable asymptomatic intervals; without urate-lowering therapy, chronic erosive arthropathy and soft-tissue urate masses become increasingly likely, especially when peaks in serum urate are high, flares are frequent, or kidney clearance pathways are impaired.

For nursing and allied staff the operational definition is pragmatic: think gout when classic joint involvement, rapid symptom evolution, and judicious fluid assessment coincide—but never close the door on septic arthritis when systemic inflammatory markers and examination findings exceed a purely crystal-mediated picture.

Nomenclature in guidelines emphasises treat-to-target serum urate regardless of staging labels; nonetheless bedside handovers benefit from language that distinguishes acute flares, inter-critical intervals, chronic gouty arthropathy, and tophaceous burden.

↔On a small screen, swipe or scroll sideways to see the full table.

Dual-energy CT or ultrasound scoring systems may assist rheumatology but are not prerequisites for initiating guideline-directed care when crystal diagnosis is already secure.

Classic teaching highlights the first metatarsophalangeal joint, yet knees, midfoot, ankles, wrists, and finger IP joints also feature—especially in older adults and in women after menopause. A usable bedside clue is the combination of extreme pain with fairly abrupt onset, exquisite tenderness to light touch, and functional inability to bear weight.

Typical features

• Monoarticular hot, swollen joint with overlying shiny skin.
• Peak intensity overnight or in early morning; prior alcohol binge or dehydration may feature in history.
• First episode may self-limit over 7–14 days even without therapy—do not interpret spontaneous improvement as proof against future flares.

Atypical or challenging patterns

• Oligo- or polyarticular flares in established disease, sometimes mistaken for rheumatoid arthritis.
• Cellulitis-overlap redness without clear tenofoil distribution—compare bilateral temperature, mark borders, repeat observations.
• Chronic low-grade ache between storms may reflect early osteoarthritis co-pathology or ergonomic compensation patterns.

Gout arises when production–excretion balance favours urate supersaturation. Renal excretion deficits dominate in many patients; dietary purines, endogenous turnover from tissue breakdown, high alcohol intake (especially beer and spirits), and fructose-sweetened beverages amplify serum peaks. Medication culprits include loop and thiazide diuretics, low-dose aspirin at analgesic doses, cyclosporine, and occasional niacin regimens—always reconcile the drug chart before attributing a flare solely to “non-adherence.”

Metabolic syndrome clustering (diabetes mellitus type 2, hypertension, truncal obesity) tracks closely with incident gout. Progressive CKD lowers the urate threshold for crystal formation and complicates both NSAID and colchicine options, pushing teams toward corticosteroid-heavy pathways when infection is excluded.

Guidelines stratify diagnosis by access to synovial analysis versus clinical–laboratory probability. Where safe, joint aspiration with polarised light microscopy remains the quickest gold standard; Gram stain and culture belong to the same specimen whenever bacterial arthritis is plausible.

Laboratory tests

• Serum urate: aids longitudinal monitoring and treatment targets; interpret cautiously mid-flare (see pearl above).
• Renal function (eGFR/creatinine), electrolytes, FBC—inform drug selection and IV fluid plans.
• Inflammatory markers to contextualise sepsis suspicion; a positive response does not prove crystal disease.

Imaging

Plain films help chronic staging (punched-out erosions with sclerotic rims); ultrasound double contour sign supports—but does not replace—crystal documentation when expert musculoskeletal ultrasound is available.

1. Suspected first flare with classic podagra, systemic features absent: activate anti-inflammatory protocol per prescriber; arrange timely primary-care or rheumatology review for urate-lowering planning.
2. Fever >38.3 °C, tachycardia disproportionate, rigors, immunosuppression, or prosthesis: septic pathway first—do not “wait for colchicine to work.”
3. CKD stage ≥3 or GI bleed risk: favour oral or parenteral corticosteroids such as prednisolone (or intra-articular steroid when monoarticular) over high-dose NSAIDs; align exact steroid route/dose with local formulary.
4. Starting urate-lowering therapy: continue flare prophylaxis (low-dose colchicine, low-dose NSAID, or low-dose steroid) for the three-to-six month window while titrating allopurinol; flag breakthrough flares early.
5. Targets not met after 6–12 months of adherent therapy: rheumatology-led escalation—not ad hoc cessation of urate lowering.

Septic bacterial arthritis remains the headline life risk; calcium pyrophosphate (pseudogout) may present with large joint effusions and fever. Cellulitis without joint violation can coexist; bursitis generates point tenderness over a bursa rather than true synovitis.

Early rheumatoid arthritis and seronegative spondyloarthritis can mimic—persistent morning stiffness >60 minutes, bilateral small-joint symmetry, or psoriatic nail changes should redirect work-up.

Acute flare anti-inflammatory therapy

High-quality guidelines endorse equivalent first-line classes: oral colchicine (low-dose loading protocols reduce diarrhoea), full anti-inflammatory NSAIDs such as naproxen or indomethacin when renal and GI risk allow, or systemic glucocorticoids when contraindications stack against the first two. Combine classes only with explicit specialist endorsement—GI and infection risks compound.

Urate-lowering therapy (ULT)

Allopurinol remains first-line xanthine oxidase inhibition for most patients, including many with CKD, using low starting doses with gradual titration and laboratory safety checks. Patients from ethnic groups with elevated HLA-B*5801 carriage require genotyping when local pathways stipulate it before first dose.

Adjunct measures

• Offload joint, elevate when feasible, apply ice 15–20 minutes several times daily unless vascular compromise exists.
• Treat precipitating dehydration when clinically indicated; avoid coercive fluid overload.
• Review nephrolithiasis history before intensifying uricosuric strategies—specialist coordination required.

Timeline-based follow-up reduces loss to care: recheck renal function and full blood count 2–4 weeks after each allopurinol dose change (sooner in CKD), repeat serum urate when steady state achieves prescriber intent, and document flare counts in clinic letters so trend—not anecdotes—drives escalation.

Bedside monitoring checklist

• Pain score at rest and on passive movement each shift until trending down.
• Temperature, HR, BP, NEWS2 (or institution equivalent) q4h until sepsis excluded.
• Stool frequency after colchicine; abdominal cramping merits pharmacist review.
• Glucose if high-dose steroids co-exist with diabetes; ketone risk if insulin-dependent.
• Skin integrity over tophi; photograph progressive breakdown for specialist communication.

• Joint destruction from repeated untreated flares.
• Tophus ulceration and secondary infection.
• Nephrolithiasis from hyperuricosuria.
• Treatment-related GI bleeding (NSAIDs), steroid hyperglycaemia, or colchicine neuromyopathy in renal failure.

Clinician-facing prevention emphasises sustained serum urate below crystal saturation, weight reduction when metabolically appropriate, substitution away from purine-heavy dietary patterns, alcohol moderation, and rationalising diuretics only when cardiology or nephrology agrees—abrupt diuretic cessation without oversight harms heart failure control.

With modern treat-to-target care, many patients achieve flare-free years and resolution of tophi, although CKD and cardiovascular comorbidity still shorten expected benefit if left unmanaged. Relapses cluster whenever urate-lowering therapy stops abruptly, alcohol excess resumes, or acute illness interrupts oral intake.

Ward teams shorten length of stay when analgesia is protocolised early, when occupational therapists intervene for safe crutch technique before transferring frail adults, and when pharmacists reconcile opioids plus NSAIDs against kidney risk. Teach patients to recognise prodromal tingling so community teams can authorize short rescue courses without duplicate ED visits.

Document joint pain distribution with simple diagrams—hand swelling over metacarpophalangeal joints or helix nodules may indicate tophaceous deposits that change mobilisation plans.

• Suspected septic arthritis or rapidly spreading skin infection.
• Colchicine toxicity: prolonged diarrhoea, marrow suppression, rising creatinine.
• Severe chest pain or sudden dyspnoea after NSAID initiation—consider GI or cardiac event.

Escalate to the medical emergency team or critical care outreach when lactate rises, systolic BP drifts below patient-specific targets, consciousness changes, or oliguria develops while inflammatory therapy is underway—each can indicate sepsis masquerading as gout.

Pre-treatment

Verify allergy history (especially prior maculopapular reactions to allopurinol), pregnancy status before radiographs or teratogenic drugs, and anticoagulation affecting aspiration timing.

Post-treatment

Monitor glucose, mood, and sleep when steroids continue beyond a few days; provide bowel regimens proactively. On discharge, ensure printed plans state whom to contact if a new hot joint develops within 72 h of ULT adjustments.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and cloze drops on the topic of septic-arthritis rule-out, CKD colchicine risk, urate-lowering prophylaxis and allopurinol vigilance—mirroring the Clinical Judgment Measurement Model emphasis on prioritisation and safe action.